DRP Cancer Tests

ALLARITY MEDICAL LABORATORY

Available DRP Cancer Tests

Over the years, Allarity Medical Laboratory has developed a comprehensive range of Drug Response Predictors (DRPs) that can be applied by other organizations for investigational or research use.

These tools provide valuable insights into the effectiveness of specific drugs based on the gene expression signatures of patients’ tumors, and may aid the development of personalized medicine and targeted therapies.

Advanced Predictive Cancer Testing using DRP

The Drug Response Predictor (DRP®) is a proprietary diagnostic platform that analyzes transcriptional (RNA) changes in tumor cells in response to various drug types. It leverages gene expression data from over 3,000 patient tumors and millions of datapoints to identify patient responders and studied in more than 35 clinical trials across numerous cancer indications and drug types. Read more about the DRP here.

Available DRP Cancer Tests

Cancer Types Covered

Allarity has made research use only (RUO) drug response predictors (DRP) for the following 16 cancer types:

  • Breast
  • Ovarian
  • RCC (Renal Cell Carcinoma)
  • Prostate
  • Endometrial
  • NSCLC (Non-Small Cell Lung Cancer)
  • HCC (Hepatocellular Carcinoma)
  • Colon
  • Glioma
  • Esophagus
  • MDS (Myelodysplastic Syndromes)
  • AML (Acute Myeloid Leukemia)
  • ALL (Acute Lymphoblastic Leukemia)
  • CLL (Chronic Lymphocytic Leukemia)
  • Myeloma
  • DLBCL (Diffuse Large B-Cell Lymphoma)
Drugs Analyzed

In parallel, Allarity has developed RUO drug response predictors for the following drugs:

# Drug Regulatory Status Scientific Publications*
1 Afatinib RUO
2 Alectinib RUO
3 Anastrozole RUO
4 Ara-C RUO
5 Arsenic trioxide RUO
6 AS605240 RUO
7 Asparaginase RUO
8 Axitinib RUO
9 AZD6482 RUO
10 AZD8055 RUO Click for report
11 Belinostat RUO Ask
12 Bendamustine RUO
13 Bleomycin RUO
14 Bortezomib RUO Link to publication
15 Bosutinib RUO
16 Busulfan RUO
17 Cabozantinib RUO
18 Capecitabine RUO
19 Carfilzomib RUO
20 Carmustine RUO
21 Cetuximab RUO
22 Clofarabine RUO
23 Cobimetinib RUO
24 CP466722 RUO
25 Crizotinib RUO
26 CUDC-101 RUO
27 CX-5461 RUO
28 Cyclophosphamide RUO
29 Dabrafenib RUO
30 Dacarbazine RUO
31 Dasatinib RUO
32 Daunorubicin RUO
33 Decitabine RUO
34 Depsipeptide RUO
35 Dexamethasone RUO
36 Docetaxel RUO
37 Dovitinib IUO Google
38 Doxorubicin RUO Link to publication
39 Epirubicin RUO Link to publication
40 Eribulin RUO
41 Erlotinib RUO
42 Estramustine RUO
43 Etoposide RUO
44 Everolimus RUO
45 Exemestane RUO
46 Fedratinib RUO
47 Fludarabine RUO
48 Fulvestrant RUO Link to publication
49 Gemcitabine RUO
50 Hydroxyurea RUO
51 Ibrutinib RUO
52 Idarubicin RUO
53 Idelalisib RUO
54 Imatinib RUO
55 Iressa RUO
56 Irinotecan RUO Link to publication
57 Irofulven RUO
58 Ixabepilone IUO
59 Ixazomib RUO
60 KU-55933 RUO
61 Lapatinib RUO
62 Lenalidomide RUO
63 Lenvatinib RUO
64 Lestaurtinib RUO
65 Leukeran RUO
66 Linifanib RUO
67 Lomustine RUO
68 Mechlorethamine RUO
69 Melphalan RUO Link to publication
70 Mercaptopurine RUO
71 Methotrexate RUO
72 Midostaurin RUO
73 Mitoxantrone RUO
74 Navitoclax RUO
75 Nilotinib RUO
76 Olaparib RUO
77 OSI-027 RUO
78 Oxaliplatin RUO
79 Paclitaxel